Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis

Encephalocraniocutaneous lipomatosis (ECCL) is a sporadic condition characterized by ocular, cutaneous, and central nervous system anomalies. Key clinical features include a well-demarcated hairless fatty nevus on the scalp, benign ocular tumors, and central nervous system lipomas. Seizures, spastic...

Full description

Saved in:
Bibliographic Details
Main Authors: Bennett, James (Author) , Moog, Ute (Author)
Format: Article (Journal)
Language:English
Published: 3 March 2016
In: The American journal of human genetics
Year: 2016, Volume: 98, Issue: 3, Pages: 579-587
ISSN:1537-6605
DOI:10.1016/j.ajhg.2016.02.006
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ajhg.2016.02.006
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0002929716000574
Get full text
Author Notes:James T. Bennett, Tiong Yang Tan, Diana Alcantara, Martine Tétrault, Andrew E. Timms, Dana Jensen, Sarah Collins, Malgorzata J. M. Nowaczyk, Marjorie J. Lindhurst, Katherine M. Christensen, Stephen R. Braddock, Heather Brandling-Bennett, Raoul C. M. Hennekam, Brian Chung, Anna Lehman, John Su, SuYuen Ng, David J. Amor, Jacek Majewski, Les G. Biesecker, Kym M. Boycott, William B. Dobyns, Mark O’Driscoll, Ute Moog, and Laura M. McDonell
Description
Summary:Encephalocraniocutaneous lipomatosis (ECCL) is a sporadic condition characterized by ocular, cutaneous, and central nervous system anomalies. Key clinical features include a well-demarcated hairless fatty nevus on the scalp, benign ocular tumors, and central nervous system lipomas. Seizures, spasticity, and intellectual disability can be present, although affected individuals without seizures and with normal intellect have also been reported. Given the patchy and asymmetric nature of the malformations, ECCL has been hypothesized to be due to a post-zygotic, mosaic mutation. Despite phenotypic overlap with several other disorders associated with mutations in the RAS-MAPK and PI3K-AKT pathways, the molecular etiology of ECCL remains unknown. Using exome sequencing of DNA from multiple affected tissues from five unrelated individuals with ECCL, we identified two mosaic mutations, c.1638C>A (p.Asn546Lys) and c.1966A>G (p.Lys656Glu) within the tyrosine kinase domain of FGFR1, in two affected individuals each. These two residues are the most commonly mutated residues in FGFR1 in human cancers and are associated primarily with CNS tumors. Targeted resequencing of FGFR1 in multiple tissues from an independent cohort of individuals with ECCL identified one additional individual with a c.1638C>A (p.Asn546Lys) mutation in FGFR1. Functional studies of ECCL fibroblast cell lines show increased levels of phosphorylated FGFRs and phosphorylated FRS2, a direct substrate of FGFR1, as well as constitutive activation of RAS-MAPK signaling. In addition to identifying the molecular etiology of ECCL, our results support the emerging overlap between mosaic developmental disorders and tumorigenesis.
Item Description:Gesehen am 06.05.2020
Physical Description:Online Resource
ISSN:1537-6605
DOI:10.1016/j.ajhg.2016.02.006